Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer
Tumor-infiltrating B-cells (TIL-B) in breast cancer (BC) have previously been associated with improved clinical outcomes; however, their role(s) in tumor immunity is not currently well known. This study confirms and extends the correlation between higher TIL-B densities and positive outcomes through an analysis of HER2-positive and triple-negative BC patients from the BIG 02-98 clinical trial (10yr mean follow-up). Fresh tissue analyses identify an increase in TIL-B density in untreated primary BC compared to normal breast tissues, which is associated with global, CD4+ and CD8+ TIL, higher tumor grades, higher proliferation and hormone receptor negativity. All B-cell differentiation stages are detectable but significant increases in memory TIL-B are consistently present. BC with higher infiltrates are specifically characterized by germinal center TIL-B, which in turn are correlated with TFH TIL and antibody-secreting TIL-B principally located in tertiary lymphoid structures. Some TIL-B also interact directly with tumor cells. Functional analyses reveal TIL-B are responsive to BCR stimulation ex vivo, express activation markers and produce cytokines and immunoglobulins despite reduced expression of the antigen-presenting molecules HLA-DR and CD40. Overall, these data support the concept that ongoing humoral immune responses are generated by TIL-B and help to generate effective anti-tumor immunity at the tumor site.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JCI insight - 5(2019) vom: 13. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garaud, Soizic [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 21.09.2020 Date Revised 21.09.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/jci.insight.129641 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300188803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300188803 | ||
| 003 | DE-627 | ||
| 005 | 20231225101957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/jci.insight.129641 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1000.xml |
| 035 | |a (DE-627)NLM300188803 | ||
| 035 | |a (NLM)31408436 | ||
| 035 | |a (PII)129641 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garaud, Soizic |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.09.2020 | ||
| 500 | |a Date Revised 21.09.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tumor-infiltrating B-cells (TIL-B) in breast cancer (BC) have previously been associated with improved clinical outcomes; however, their role(s) in tumor immunity is not currently well known. This study confirms and extends the correlation between higher TIL-B densities and positive outcomes through an analysis of HER2-positive and triple-negative BC patients from the BIG 02-98 clinical trial (10yr mean follow-up). Fresh tissue analyses identify an increase in TIL-B density in untreated primary BC compared to normal breast tissues, which is associated with global, CD4+ and CD8+ TIL, higher tumor grades, higher proliferation and hormone receptor negativity. All B-cell differentiation stages are detectable but significant increases in memory TIL-B are consistently present. BC with higher infiltrates are specifically characterized by germinal center TIL-B, which in turn are correlated with TFH TIL and antibody-secreting TIL-B principally located in tertiary lymphoid structures. Some TIL-B also interact directly with tumor cells. Functional analyses reveal TIL-B are responsive to BCR stimulation ex vivo, express activation markers and produce cytokines and immunoglobulins despite reduced expression of the antigen-presenting molecules HLA-DR and CD40. Overall, these data support the concept that ongoing humoral immune responses are generated by TIL-B and help to generate effective anti-tumor immunity at the tumor site | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a B cells | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Oncology | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 650 | 7 | |a ERBB2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Buisseret, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Solinas, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Gu-Trantien, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a de Wind, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Van den Eynden, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Naveaux, Celine |e verfasserin |4 aut | |
| 700 | 1 | |a Lodewyckx, Jean-Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Boisson, Anaïs |e verfasserin |4 aut | |
| 700 | 1 | |a Duvillier, Hughes |e verfasserin |4 aut | |
| 700 | 1 | |a Craciun, Ligia |e verfasserin |4 aut | |
| 700 | 1 | |a Ameye, Lieveke |e verfasserin |4 aut | |
| 700 | 1 | |a Veys, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Paesmans, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Larsimont, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Piccart-Gebhart, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Willard-Gallo, Karen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCI insight |d 2016 |g 5(2019) vom: 13. Aug. |w (DE-627)NLM257703918 |x 2379-3708 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2019 |g day:13 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/jci.insight.129641 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2019 |b 13 |c 08 | ||